Immunology
Global

Immunology Experts

Jason b. brayer

Researcher
Deparment of Immunology
Moffitt Cancer Center
United States of America

Jason b. brayer

Biography

Dr. Jason B. Brayer is affiliated to Deparment of Immunology, Moffitt Cancer Center. Dr. Jason B. Brayer is currently providing services as Researcher. Dr. Jason B. Brayer has authored and co-authored multiple peer-reviewed scientific papers and presented works at many national and International conferences. Dr. Jason B. Brayer contributions have acclaimed recognition from honourable subject experts around the world. Dr. Jason B. Brayer is actively associated with different societies and academies. Dr. Jason B. Brayer academic career is decorated with several reputed awards and funding. Dr. Jason B. Brayer research interests include Exploring the therapeutic potential of HDAC11 inhibitors in the treatment of multiple myeloma. Exploring the potential for selective HDAC11 inhibitors to enhance T cell responses in the context of immunotherapy, including vaccine-based and cellular adoptive therapeutic approaches. Defining the functional significance of the interaction between HDAC11 and IRF4 and its impact as a regulator of CD8 T cell function. Defining the functional significance of the interaction between HDAC11 and IRF4 as it relates to myeloma cell development and survival.

Research Interest

Exploring the therapeutic potential of HDAC11 inhibitors in the treatment of multiple myeloma. Exploring the potential for selective HDAC11 inhibitors to enhance T cell responses in the context of immunotherapy, including vaccine-based and cellular adoptive therapeutic approaches. Defining the functional significance of the interaction between HDAC11 and IRF4 and its impact as a regulator of CD8 T cell function. Defining the functional significance of the interaction between HDAC11 and IRF4 as it relates to myeloma cell development and survival

Publications

  • Dalia S, Brayer J, Horna P, Zhang H, Pinilla-Ibarz J. Transformation to Hodgkin lymphoma in chronic lymphocytic leukemia coexisting with Epstein–Barr viremia. Leukemia & lymphoma. 2014 Nov 1;55(11):2660-2.

  • WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides

  • Brayer J, Baz R. The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma. Therapeutic advances in hematology. 2017 Jul;8(7):209-20.

Global Experts from United States of America

Global Experts in Subject

Share This Profile